Real‐world clinical outcomes of olaparib therapy in Chinese patients with advanced serous ovarian cancer treated in Macau
Author:
Affiliation:
1. Department of OncologyKiang Wu Hospital Macau SAR China
2. Department of Laboratorythe Fifth Affiliated Hospital of Sun Yat‐Sen University Zhuhai China
Funder
AstraZeneca Hong Kong
Publisher
Wiley
Subject
Cancer Research,Oncology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/cnr2.1180
Reference37 articles.
1. Global cancer statistics
2. Cancer statistics in China, 2015
3. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
4. Improvement in the prognosis of ovarian cancer in the era before addition of molecular targeting therapy
5. Trends in Relative Survival for Ovarian Cancer From 1975 to 2011
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Liquid biopsy in ovarian cancer in China and the world: current status and future perspectives;Frontiers in Oncology;2023-12-19
2. Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study;BMC Cancer;2022-11-08
3. The first Chinese National Union of Real‐world Gynaecological Oncology Research and Patient Management Platform: A retrospective study;BJOG: An International Journal of Obstetrics & Gynaecology;2022-11
4. Transferable Query Selection for Active Domain Adaptation;2021 IEEE/CVF Conference on Computer Vision and Pattern Recognition (CVPR);2021-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3